HUP9603305A2 - [(pyrrolyl-carbonyl)-amino]-naphtalene derivatives, capable for improving biological availability of biologically active compounds - Google Patents
[(pyrrolyl-carbonyl)-amino]-naphtalene derivatives, capable for improving biological availability of biologically active compoundsInfo
- Publication number
- HUP9603305A2 HUP9603305A2 HU9603305A HUP9603305A HUP9603305A2 HU P9603305 A2 HUP9603305 A2 HU P9603305A2 HU 9603305 A HU9603305 A HU 9603305A HU P9603305 A HUP9603305 A HU P9603305A HU P9603305 A2 HUP9603305 A2 HU P9603305A2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrrolyl
- carbonyl
- amino
- biologically active
- active compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- -1 pyrrolyl-carbonyl Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9504065.5A GB9504065D0 (en) | 1995-03-01 | 1995-03-01 | Poly-pyrrolecarboxamidonaphthalenic acid derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9603305A2 true HUP9603305A2 (en) | 1997-08-28 |
| HUP9603305A3 HUP9603305A3 (en) | 1998-01-28 |
Family
ID=10770421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9603305A HUP9603305A3 (en) | 1995-03-01 | 1996-02-08 | [(pyrrolyl-carbonyl)-amino]-naphtalene derivatives, capable for improving biological availability of biologically active compounds |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0758339A1 (en) |
| JP (1) | JPH10504319A (en) |
| KR (1) | KR970702868A (en) |
| CN (1) | CN1148391A (en) |
| AR (1) | AR002280A1 (en) |
| AU (1) | AU696470B2 (en) |
| CA (1) | CA2189358A1 (en) |
| EA (1) | EA000006B1 (en) |
| FI (1) | FI964331A (en) |
| GB (1) | GB9504065D0 (en) |
| HU (1) | HUP9603305A3 (en) |
| IL (1) | IL117193A0 (en) |
| MX (1) | MX9605089A (en) |
| NO (1) | NO964610L (en) |
| NZ (1) | NZ302267A (en) |
| PL (1) | PL317094A1 (en) |
| WO (1) | WO1996026950A1 (en) |
| ZA (1) | ZA961636B (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0934329B1 (en) * | 1996-09-30 | 2001-12-12 | Bayer Ag | Glycoconjugates from modified camptothecin derivates (20-o-linkage) |
| DE19640969A1 (en) * | 1996-10-04 | 1998-04-16 | Bayer Ag | 20-0 linked glycoconjugates from camptothecin |
| ID23424A (en) * | 1997-05-14 | 2000-04-20 | Bayer Ag | GLIKOKONJUGUS OF 20 (S) -CAMPTOTESIN |
| GB9713733D0 (en) * | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Poly-branched polycarboxamido compounds |
| GB9713732D0 (en) * | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Substituted triazinic compounds |
| US6485514B1 (en) * | 1997-12-12 | 2002-11-26 | Supergen, Inc. | Local delivery of therapeutic agents |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
| US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
| US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US6777425B2 (en) | 2001-06-13 | 2004-08-17 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
| JP5183010B2 (en) * | 2002-05-16 | 2013-04-17 | グリコミメティクス， インコーポレイテッド | Compounds and methods for inhibiting selectin-mediated functions |
| WO2003101998A1 (en) | 2002-06-03 | 2003-12-11 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
| WO2004012736A1 (en) | 2002-08-02 | 2004-02-12 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
| US7265129B2 (en) | 2002-10-25 | 2007-09-04 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
| WO2004052304A2 (en) | 2002-12-10 | 2004-06-24 | Oscient Pharmaceuticals Corporation | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif |
| DK2264043T3 (en) | 2005-09-02 | 2018-01-29 | Glycomimetics Inc | Heterobifunctional pan-selectin inhibitors |
| US7875602B2 (en) | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
| US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| WO2011163572A2 (en) * | 2010-06-24 | 2011-12-29 | University Of Kansas | Bifunctional conjugate compositions and associated methods |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| KR102055958B1 (en) | 2011-12-22 | 2019-12-13 | 글리코미메틱스, 인크. | E-selectin antagonist compounds, compositions, and methods of use |
| US9867841B2 (en) | 2012-12-07 | 2018-01-16 | Glycomimetics, Inc. | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells |
| JP6689854B2 (en) | 2014-12-03 | 2020-04-28 | グリコミメティクス， インコーポレイテッド | Heterobifunctional inhibitors of E-selectin and CXCR4 chemokine receptors |
| CA3009836A1 (en) | 2016-01-22 | 2017-07-27 | Glycomimetics, Inc. | Glycomimetic inhibitors of pa-il and pa-iil lectins |
| WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
| EP3497131B1 (en) | 2016-08-08 | 2022-03-09 | GlycoMimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4. |
| KR102607640B1 (en) | 2016-10-07 | 2023-11-28 | 글리코미메틱스, 인크. | Very potent multimeric E-selectin antagonist |
| US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
| EP3381897A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer |
| EP3717013A1 (en) | 2017-11-30 | 2020-10-07 | GlycoMimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| AU2018395417B2 (en) | 2017-12-29 | 2023-07-13 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| CA3091454A1 (en) | 2018-03-05 | 2019-09-12 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| WO2021118927A1 (en) | 2019-12-13 | 2021-06-17 | Insideoutbio, Inc. | Methods and compositions for targeted delivery of nucleic acid therapeutics |
| CN114933569A (en) * | 2022-04-07 | 2022-08-23 | 澳门科技大学 | Sphingolipid compound, liposome containing sphingolipid compound and application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| GB9216962D0 (en) * | 1992-08-11 | 1992-09-23 | Erba Carlo Spa | Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives |
| GB9304589D0 (en) * | 1993-03-05 | 1993-04-21 | Erba Carlo Spa | Biologically active ureido derivatives useful as antimetastic agents |
| GB9307948D0 (en) * | 1993-04-16 | 1993-06-02 | Erba Carlo Spa | Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease |
| GB9403909D0 (en) * | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
-
1995
- 1995-03-01 GB GBGB9504065.5A patent/GB9504065D0/en active Pending
-
1996
- 1996-02-08 JP JP8525980A patent/JPH10504319A/en active Pending
- 1996-02-08 HU HU9603305A patent/HUP9603305A3/en unknown
- 1996-02-08 MX MX9605089A patent/MX9605089A/en unknown
- 1996-02-08 EP EP96904024A patent/EP0758339A1/en not_active Withdrawn
- 1996-02-08 WO PCT/EP1996/000528 patent/WO1996026950A1/en not_active Application Discontinuation
- 1996-02-08 PL PL96317094A patent/PL317094A1/en unknown
- 1996-02-08 CA CA002189358A patent/CA2189358A1/en not_active Abandoned
- 1996-02-08 EA EA199600104A patent/EA000006B1/en not_active IP Right Cessation
- 1996-02-08 CN CN96190152A patent/CN1148391A/en active Pending
- 1996-02-08 NZ NZ302267A patent/NZ302267A/en unknown
- 1996-02-08 AU AU48698/96A patent/AU696470B2/en not_active Ceased
- 1996-02-20 IL IL11719396A patent/IL117193A0/en unknown
- 1996-02-29 ZA ZA961636A patent/ZA961636B/en unknown
- 1996-02-29 AR ARP960101576A patent/AR002280A1/en unknown
- 1996-10-28 FI FI964331A patent/FI964331A/en unknown
- 1996-10-31 NO NO964610A patent/NO964610L/en unknown
- 1996-11-01 KR KR1019960706263A patent/KR970702868A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9603305A3 (en) | 1998-01-28 |
| KR970702868A (en) | 1997-06-10 |
| JPH10504319A (en) | 1998-04-28 |
| IL117193A0 (en) | 1996-06-18 |
| GB9504065D0 (en) | 1995-04-19 |
| CN1148391A (en) | 1997-04-23 |
| AR002280A1 (en) | 1998-03-11 |
| FI964331A0 (en) | 1996-10-28 |
| NZ302267A (en) | 1997-10-24 |
| PL317094A1 (en) | 1997-03-17 |
| AU696470B2 (en) | 1998-09-10 |
| NO964610D0 (en) | 1996-10-31 |
| ZA961636B (en) | 1996-09-06 |
| MX9605089A (en) | 1997-12-31 |
| AU4869896A (en) | 1996-09-18 |
| EA199600104A1 (en) | 1997-09-30 |
| CA2189358A1 (en) | 1996-09-06 |
| WO1996026950A1 (en) | 1996-09-06 |
| NO964610L (en) | 1996-10-31 |
| EA000006B1 (en) | 1997-12-30 |
| FI964331A (en) | 1996-11-01 |
| EP0758339A1 (en) | 1997-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9603305A2 (en) | [(pyrrolyl-carbonyl)-amino]-naphtalene derivatives, capable for improving biological availability of biologically active compounds | |
| PL323152A1 (en) | Derivatives of 1,3-propanodiole as biologically active compounds | |
| ZA965866B (en) | 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | |
| HK1001860A1 (en) | I-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients | |
| ZA977524B (en) | Process for the preparation of bone cements comprising active compound. | |
| HUT74604A (en) | Process for the preparation of concentrated, biologically active silicon compounds | |
| ZA968956B (en) | Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients | |
| AU8166098A (en) | Removal of biologically active agents | |
| AU7073096A (en) | Inhibited biological degradation of oligodeoxynucleotides | |
| AU4515996A (en) | Methods for increasing the bioavailability of biological active agents | |
| AU2380595A (en) | Biologically active composition | |
| AU4217197A (en) | Biologically active phosphotriester-type compounds | |
| AU1198397A (en) | Sustained-release microgranules containing diltiazem as active principle | |
| HU9600272D0 (en) | 10-amino-aliphatic-dibenzo-[b,f]oxepines of antineurodegenerative activity | |
| HU9502426D0 (en) | Compounds of pharmaceutical activity | |
| IL117943A0 (en) | Dihalopropene compounds, insecticides containing them as active ingredients and intermediates for their production | |
| IL142502A0 (en) | Intermediates for the preparation of biologically active benzothiazolone ethanamines | |
| AU1407197A (en) | Stable vancomycin hydrochloride solutions | |
| AU6229898A (en) | Derivatives of cyclodepsipeptide, pf1022 substance | |
| AU1952292A (en) | Applicator for biologically active substance | |
| AU3109995A (en) | Process for the preparation of spherical microparticles containing biologically active compounds | |
| AU6837698A (en) | Method for obtaining novel biologically active substances, resulting substance s and compositions containing same | |
| AU713086C (en) | 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta, 20-epoxy-1- hydroxy-9-oxo-19-norcyclopropa(g)tax-11-en-13alpha-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3- phenylpropionate dihydrate and its process of preparation | |
| IL133533A0 (en) | Non-immunosuppressive compounds, process for their preparation and different uses thereof | |
| GB9521497D0 (en) | Biological compounds |